Gemina Laboratories (XCNQ:GLAB) Capex-to-Operating-Cash-Flow : -2.00 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Gemina Laboratories's Capital Expenditure for the three months ended in Jan. 2024 was C$0.02 Mil. Its Cash Flow from Operations for the three months ended in Jan. 2024 was C$0.01 Mil.

Hence, Gemina Laboratories's Capex-to-Operating-Cash-Flow for the three months ended in Jan. 2024 was -2.00.

Gemina Laboratories Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Gemina Laboratories's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Capex-to-Operating-Cash-Flow Chart

Gemina Laboratories Annual Data

Trend

Jan21

Jan22

Jan23

Jan24

Capex-to-Operating-Cash-Flow

Gemina Laboratories Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial							-	-	-	-	-2.00

Competitive Comparison of Gemina Laboratories's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Gemina Laboratories's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gemina Laboratories's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Capex-to-Operating-Cash-Flow falls into.

Gemina Laboratories Capex-to-Operating-Cash-Flow Calculation

Gemina Laboratories's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jan. 2024 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (-0.041)	/	-3.244
	=	N/A

Gemina Laboratories's Capex-to-Operating-Cash-Flow for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (0.016)	/	0.008
	=	-2.00

Gemina Laboratories (XCNQ:GLAB) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

Gemina Laboratories Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Gemina Laboratories (XCNQ:GLAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Capex-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

GLABF:USA

Address

3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8

Website

https://www.geminalabs.com

Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.

Executives

James Damian Tansey

Director

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines